<rst>
	<header>
		<relations>
			<rel name="antithesis" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="elaboration" type="rst"/>
			<rel name="evaluation" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="justify" type="rst"/>
			<rel name="motivation" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="multinuc"/>
			<rel name="restatement" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="solutionhood" type="rst"/>
		</relations>
	</header>
	<body>
		<segment id="1" parent="2" relname="circumstance">So it is work in progress?</segment>
		<segment id="2" parent="22" relname="span">Unidentified Analyst Yes. So there's nothing yet that is kind of last preclinical stages, there's still some room to go?</segment>
		<segment id="3" parent="22" relname="circumstance">Albert Bourla Yes.</segment>
		<segment id="4" parent="5" relname="condition">Unidentified Analyst Okay. Let's move away from just talking about the COVID space or the mRNA space.</segment>
		<segment id="5" >And let's talk about your growth profile.</segment>
		<segment id="6" parent="7" relname="concession">So one of the questions I always find</segment>
		<segment id="7" >when I look at Pfizer is the problem the company has of having the biggest product it has ex-COVID being less than 15% of revenue.</segment>
		<segment id="8" parent="9" relname="condition">Investors struggle a little bit with this idea of a highly diversified company.</segment>
		<segment id="9" >Financially, it makes a lot of sense.</segment>
		<segment id="10" parent="11" relname="evaluation">But like a lot of times I argue that there is nothing in the Pfizer portfolio</segment>
		<segment id="11" parent="23" relname="evaluation">which is potentially moving the revenue growth up in a significant way.</segment>
		<segment id="12" parent="23" relname="elaboration">It's more for multiple products.</segment>
		<segment id="13" parent="14" relname="concession">Have you run into this as an issue?</segment>
		<segment id="14" parent="24" relname="circumstance">And how do you answer this argument that unlike companies like Lilly,</segment>
		<segment id="15" parent="24" relname="circumstance">which has two of those or AbbVie,</segment>
		<segment id="16" parent="15" relname="elaboration">which is the immunology franchise,</segment>
		<segment id="17" parent="18" relname="circumstance">Pfizer is a lot more of a conglomerate of broader portfolio of products</segment>
		<segment id="18" >as supposed to be driven by one or two big markets?</segment>
		<segment id="19" parent="20" relname="concession">Albert Bourla Look, to answer this question, you made a lot of assumptions, right?</segment>
		<segment id="20" parent="25" relname="span">Unidentified Analyst Correct my assumptions.</segment>
		<segment id="21" parent="25" relname="circumstance">Albert Bourla Excluding COVID, we have two that they are way more than 50 right now.</segment>
		<group id="22" type="span" />
		<group id="23" type="span" />
		<group id="24" type="span" />
		<group id="25" type="span" />
	</body>
</rst>
